Yao Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yao Tian has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Yingxi Li
Health Science Center, Ningbo University
10 shared publicationsGuixin Wang
The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
6 shared publicationsWenbin Song
Department of General Surgery, Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair, Tianjin Medical University General Hospital, Tianjin General Surgery Institute, Tianjin, China
6 shared publicationsZhaohui Chen
The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
5 shared publicationsZhaoyi Liu
Department of General Surgery, Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair, Tianjin Medical University General Hospital, Tianjin General Surgery Institute, Tianjin, China
5 shared publicationsLong He
Department of Thyroid and Breast Surgery, Bishan Hospital of Chongqing Medical University
4 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1914292
Integrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewiring and immune evasion
Background: Esophageal squamous cell carcinoma (ESCC) has high mortality, and metastasis is the leading cause of patient death. Neuromedin B (NMB) promotes tumor development in various cancers, yet its role in ESCC metastasis remains unclear. Methods: We integrated single-cell transcriptomic data from matched primary and metastatic ESCC lesions (GSE309392) with bulk transcriptomic cohorts from TCGA and GSE53624. In silico gene perturbation, ligand-receptor communication analysis, and single-cell prognostic model construction were performed, followed by functional validation through siRNA-mediated NMB knockdown in TE-1 and KYSE30 cell lines. Results: NMB was identified as a key gene enriched in metastatic ESCC lesions, and its high expression was associated with coordinated upregulation of oxidative phosphorylation pathway genes and aldo-keto reductase family antioxidant enzymes (AKR1C1, AKR1C2, AKR1B10). Genomic analysis revealed that NMB-high tumors carried a higher clonal mutation burden and a markedly increased frequency of NFE2L2 activating mutations (23% vs . 8%, P = 0.04). In silico knockout and correlation analysis identified AKR1C1 as a downstream effector of NMB. NMB expression was negatively correlated with CD8 + T cell and activated NK cell infiltration. CellChat analysis revealed communication between NMB-positive cells and monocytes via the TGM2–ADGRG1 axis, and specifically detected IFNG signaling. In the single-cell prognostic model, NMB-positive cells accounted for 50% of the high-risk group but only 20% of the low-risk group. TCGA-based survival analysis demonstrated that high NMB expression was associated with shorter overall survival (HR = 2.98, P = 0.03). In vitro NMB-targeted RNA interference markedly inhibited proliferation, colony formation, and migration in TE-1 and KYSE30 cells. CMap screening identified the endothelin-PDE5-cGMP axis as a potential therapeutic target. Conclusion: NMB serves as a key driver of metastatic adaptation in ESCC, conferring a survival advantage to tumor cells during metastatic colonization through genomic evolution and immune remodeling, with metabolic adaptation as a downstream consequence of genomic alterations.
- 31 August 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1914292
Open AccessIntegrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewiring and immune evasion
Background: Esophageal squamous cell carcinoma (ESCC) has high mortality, and metastasis is the leading cause of patient death. Neuromedin B (NMB) promotes tumor development in various cancers, yet its role in ESCC metastasis remains unclear. Methods: We integrated single-cell transcriptomic data from matched primary and metastatic ESCC lesions (GSE309392) with bulk transcriptomic cohorts from TCGA and GSE53624. In silico gene perturbation, ligand-receptor communication analysis, and single-cell prognostic model construction were performed, followed by functional validation through siRNA-mediated NMB knockdown in TE-1 and KYSE30 cell lines. Results: NMB was identified as a key gene enriched in metastatic ESCC lesions, and its high expression was associated with coordinated upregulation of oxidative phosphorylation pathway genes and aldo-keto reductase family antioxidant enzymes (AKR1C1, AKR1C2, AKR1B10). Genomic analysis revealed that NMB-high tumors carried a higher clonal mutation burden and a markedly increased frequency of NFE2L2 activating mutations (23% vs . 8%, P = 0.04). In silico knockout and correlation analysis identified AKR1C1 as a downstream effector of NMB. NMB expression was negatively correlated with CD8 + T cell and activated NK cell infiltration. CellChat analysis revealed communication between NMB-positive cells and monocytes via the TGM2–ADGRG1 axis, and specifically detected IFNG signaling. In the single-cell prognostic model, NMB-positive cells accounted for 50% of the high-risk group but only 20% of the low-risk group. TCGA-based survival analysis demonstrated that high NMB expression was associated with shorter overall survival (HR = 2.98, P = 0.03). In vitro NMB-targeted RNA interference markedly inhibited proliferation, colony formation, and migration in TE-1 and KYSE30 cells. CMap screening identified the endothelin-PDE5-cGMP axis as a potential therapeutic target. Conclusion: NMB serves as a key driver of metastatic adaptation in ESCC, conferring a survival advantage to tumor cells during metastatic colonization through genomic evolution and immune remodeling, with metabolic adaptation as a downstream consequence of genomic alterations.
- Open Access
- 16 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1784914
Noninvasive assessment of core metastatic genes in lung adenocarcinoma: development of a predictive model integrating single-cell transcriptomics and radiomics
Background: Lung adenocarcinoma (LUAD) leads to death primarily due to its high metastatic potential. Risk assessment methodologies currently predicated on histopathological and imaging features possess a limited capacity to predict metastatic potential. Therefore, integrating single-cell transcriptomics and CT radiomics to identify key molecular drivers of metastasis and establishing a noninvasive imaging prediction model for LUAD is important. Methods: Bulk transcriptomic data and single-cell RNA sequencing (scRNA-seq) data were obtained from public database for analysis. Analytical tools (Seurat, inferCNV, Monocle, WGCNA, LASSO regression, GO/KEGG/GSEA, CellChat) were used for cellular profiling, trajectory analysis, gene identification, functional enrichment, and cell–cell communication. Immunohistochemistry (IHC) and RT-qPCR validated candidate genes at protein and mRNA levels. Additionally, a CT radiomics-based predictive model was developed for noninvasive gene expression assessment. Results: ScRNA-seq analysis revealed a malignant cellular trajectory from primary to metastatic LUAD and identified a metastasis-associated subpopulation. Three consistently overexpressed genes (PSMB5, PSMB7 and SLC16A3) were correlated with poor prognosis. Functional studies indicated their synergistic roles in promoting tumor progression through cell cycle regulation, proteasome activity, and metabolic reprogramming. A CT radiomics model effectively predicted the combined expression of these genes (AUC = 0.765), linking imaging features to molecular phenotypes. Conclusion: This study reveals that the synergistic expression pattern of PSMB5, PSMB7 and SLC16A3 is closely associated with lung adenocarcinoma metastasis and poor prognosis, confirming their potential value as prognostic biomarkers and therapeutic targets. The CT radiomics model offers a noninvasive tool for molecular phenotyping, aiding in preoperative precision assessment and advancing noninvasive clinical decision-making for LUAD.
- 16 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1784914
Open AccessNoninvasive assessment of core metastatic genes in lung adenocarcinoma: development of a predictive model integrating single-cell transcriptomics and radiomics
Background: Lung adenocarcinoma (LUAD) leads to death primarily due to its high metastatic potential. Risk assessment methodologies currently predicated on histopathological and imaging features possess a limited capacity to predict metastatic potential. Therefore, integrating single-cell transcriptomics and CT radiomics to identify key molecular drivers of metastasis and establishing a noninvasive imaging prediction model for LUAD is important. Methods: Bulk transcriptomic data and single-cell RNA sequencing (scRNA-seq) data were obtained from public database for analysis. Analytical tools (Seurat, inferCNV, Monocle, WGCNA, LASSO regression, GO/KEGG/GSEA, CellChat) were used for cellular profiling, trajectory analysis, gene identification, functional enrichment, and cell–cell communication. Immunohistochemistry (IHC) and RT-qPCR validated candidate genes at protein and mRNA levels. Additionally, a CT radiomics-based predictive model was developed for noninvasive gene expression assessment. Results: ScRNA-seq analysis revealed a malignant cellular trajectory from primary to metastatic LUAD and identified a metastasis-associated subpopulation. Three consistently overexpressed genes (PSMB5, PSMB7 and SLC16A3) were correlated with poor prognosis. Functional studies indicated their synergistic roles in promoting tumor progression through cell cycle regulation, proteasome activity, and metabolic reprogramming. A CT radiomics model effectively predicted the combined expression of these genes (AUC = 0.765), linking imaging features to molecular phenotypes. Conclusion: This study reveals that the synergistic expression pattern of PSMB5, PSMB7 and SLC16A3 is closely associated with lung adenocarcinoma metastasis and poor prognosis, confirming their potential value as prognostic biomarkers and therapeutic targets. The CT radiomics model offers a noninvasive tool for molecular phenotyping, aiding in preoperative precision assessment and advancing noninvasive clinical decision-making for LUAD.
- Open Access
- 10 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1695689
Multi-scale data reveal a CD24(+) MUCL1(+) tumor subgroup associated with unfavorable prognosis in ER+ breast cancer
Objective: Breast cancer remains the leading cause of cancer-associated death for women globally. For the group of ER+ breast cancer patients, there are still some problems of poor prognosis that need to be solved. This study aims to identify the poor prognostic tumor subgroups for the prognostic stratification of ER+ patients.Methods: Through a comprehensive multi-omics strategy, we systematically characterized the biological and clinical significance of MUCL1+CD24+ cells in breast cancer, and we used multiplex immunohistochemistry to confirm the poor role of MUCL1+CD24+ cells.Results: Single-cell transcriptomics unraveled the cellular ontogeny and immune microenvironment interactions of this subset, while bulk RNA sequencing exposed significant pathway heterogeneity and differential immunotherapy responses associated with varying cellular abundance levels. Genomic landscape analysis pinpointed specific somatic mutations correlated with MUCL1(+) CD24(+) cell infiltration patterns, findings that were subsequently validated through multiplex immunohistochemistry to demonstrate strong prognostic value. Crucially, we developed a clinically translatable radiomics approach that successfully correlated specific MRI features with cellular prevalence, establishing a foundation for noninvasive detection of this aggressive cellular subpopulation.Conclusions: This integrative approach, spanning molecular to imaging analyses, provides novel insights into both the biological drivers and clinical implications of MUCL1(+) CD24(+) cells in breast cancer progression.
- 10 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1695689
Open AccessMulti-scale data reveal a CD24(+) MUCL1(+) tumor subgroup associated with unfavorable prognosis in ER+ breast cancer
Objective: Breast cancer remains the leading cause of cancer-associated death for women globally. For the group of ER+ breast cancer patients, there are still some problems of poor prognosis that need to be solved. This study aims to identify the poor prognostic tumor subgroups for the prognostic stratification of ER+ patients.Methods: Through a comprehensive multi-omics strategy, we systematically characterized the biological and clinical significance of MUCL1+CD24+ cells in breast cancer, and we used multiplex immunohistochemistry to confirm the poor role of MUCL1+CD24+ cells.Results: Single-cell transcriptomics unraveled the cellular ontogeny and immune microenvironment interactions of this subset, while bulk RNA sequencing exposed significant pathway heterogeneity and differential immunotherapy responses associated with varying cellular abundance levels. Genomic landscape analysis pinpointed specific somatic mutations correlated with MUCL1(+) CD24(+) cell infiltration patterns, findings that were subsequently validated through multiplex immunohistochemistry to demonstrate strong prognostic value. Crucially, we developed a clinically translatable radiomics approach that successfully correlated specific MRI features with cellular prevalence, establishing a foundation for noninvasive detection of this aggressive cellular subpopulation.Conclusions: This integrative approach, spanning molecular to imaging analyses, provides novel insights into both the biological drivers and clinical implications of MUCL1(+) CD24(+) cells in breast cancer progression.
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1659183
Multiomics profiling identifies the poor prognostic role of a tumor cluster with GNA15 overexpression in triple-negative breast cancer
Background: Tumor heterogeneity impacts invasive behaviors, treatment response, and clinical outcomes in triple-negative breast cancer (TNBC). However, this heterogeneity remains incompletely characterized. This study aims to utilize multi-scale data to investigate inter-tumoral heterogeneity and identify potential TNBC biomarkers.Methods: Single-cell RNA expression profiles were analyzed using R packages. Specifically, the infercnv, Pyscenic, GeneNMF, SCP, Vector, CellChat, and hdWGCNA packages were employed to identify malignant cells and characterize heterogeneity in transcription factors, metaprograms, lineage evolution, developmental trajectories, cell–cell interactions, and co-expression networks. Bulk RNA datasets were incorporated to assess the prognostic value of cell clusters and candidate genes. G Protein Subunit Alpha 15 (GNA15) expression was determined via reverse transcription–quantitative PCR (RT–qPCR) and immunohistochemistry. Cell functional assays were performed to evaluate proliferation, migration, and invasion capabilities.Results: A total of 14,335 malignant cells were isolated from epithelial cells across 15 single-cell RNA samples. Six tumor cell clusters were identified, which exhibited distinct prognoses, biological functions, driver transcription factors, and co-expression networks. Notably, the S2 cluster demonstrated association with multiple malignancy-related pathways and inferior survival outcomes. GNA15 emerged as the S2 cluster hub gene. In vitro experiments confirmed that GNA15 knockdown significantly attenuated proliferation, migration, and invasion in TNBC cell lines.Conclusions: Our study comprehensively delineated TNBC tumor cell heterogeneity and established the critical role of GNA15 in TNBC progression. These findings enhance the understanding of TNBC heterogeneity and provide a theoretical foundation for TNBC treatment.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1659183
Open AccessMultiomics profiling identifies the poor prognostic role of a tumor cluster with GNA15 overexpression in triple-negative breast cancer
Background: Tumor heterogeneity impacts invasive behaviors, treatment response, and clinical outcomes in triple-negative breast cancer (TNBC). However, this heterogeneity remains incompletely characterized. This study aims to utilize multi-scale data to investigate inter-tumoral heterogeneity and identify potential TNBC biomarkers.Methods: Single-cell RNA expression profiles were analyzed using R packages. Specifically, the infercnv, Pyscenic, GeneNMF, SCP, Vector, CellChat, and hdWGCNA packages were employed to identify malignant cells and characterize heterogeneity in transcription factors, metaprograms, lineage evolution, developmental trajectories, cell–cell interactions, and co-expression networks. Bulk RNA datasets were incorporated to assess the prognostic value of cell clusters and candidate genes. G Protein Subunit Alpha 15 (GNA15) expression was determined via reverse transcription–quantitative PCR (RT–qPCR) and immunohistochemistry. Cell functional assays were performed to evaluate proliferation, migration, and invasion capabilities.Results: A total of 14,335 malignant cells were isolated from epithelial cells across 15 single-cell RNA samples. Six tumor cell clusters were identified, which exhibited distinct prognoses, biological functions, driver transcription factors, and co-expression networks. Notably, the S2 cluster demonstrated association with multiple malignancy-related pathways and inferior survival outcomes. GNA15 emerged as the S2 cluster hub gene. In vitro experiments confirmed that GNA15 knockdown significantly attenuated proliferation, migration, and invasion in TNBC cell lines.Conclusions: Our study comprehensively delineated TNBC tumor cell heterogeneity and established the critical role of GNA15 in TNBC progression. These findings enhance the understanding of TNBC heterogeneity and provide a theoretical foundation for TNBC treatment.
- Open Access
- 24 July 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (11) , 3314-3328
Integrating Bulk RNA and Single-cell transcriptome to explore the role of glycan-related genes in lung adenocarcinoma
Background: Despite significant advancements in the diagnosis and therapeutic management of lung adenocarcinoma (LUAD), patient outcomes continue to be suboptimal, primarily attributable to the intricate of the tumor microenvironment (TME). Recently, attention has been paid to the role of glycans and their glycosylation modifications in tumor progression.
- 24 July 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (11) , 3314-3328
Open AccessIntegrating Bulk RNA and Single-cell transcriptome to explore the role of glycan-related genes in lung adenocarcinoma
Background: Despite significant advancements in the diagnosis and therapeutic management of lung adenocarcinoma (LUAD), patient outcomes continue to be suboptimal, primarily attributable to the intricate of the tumor microenvironment (TME). Recently, attention has been paid to the role of glycans and their glycosylation modifications in tumor progression.
- Open Access
- 7 April 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-16
Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer
Gamma-delta (γδ) T cells are a critical component of the tumor microenvironment and have been recognized as a promising biomarker and target for cancer therapy. Increasing evidence suggests that γδT cells play distinct roles in different cancers. However, the impact of γδT cells in breast cancer remains controversial. In this study, we investigated the role of γδT cells in breast cancer using a comprehensive approach, including bulk and single-cell sequencing, radiomics based on magnetic resonance imaging (MRI), genomic data, and immunohistochemistry. Single-cell RNA profiling was used to infer the potential lineage evolution of γδT cells and their interactions with other immune cells. Bulk RNA sequencing was included to uncover the heterogeneity in signaling pathways, as well as radiotherapy and immunotherapy responses, among patients with varying levels of γδT cell abundance. Genomic analysis was used to recognize the critical gene mutations with the infiltration of γδT cells. Immunohistochemistry was performed to validate the prognostic value of γδT cells in breast cancer patients. Lastly, radiomics was used to establish a correlation between the abundance of γδT cells and the features of MRI images. The γδT cell infiltration was closely associated with favorable prognosis in triple-negative breast cancer (TNBC) but not in other subtypes of breast cancer. γδT cells may exert antitumor effects through intrinsic lineage evolution or interact with antigen-presenting cells through ligand-receptor pairs. Patients with a high γδT cell abundance may benefit more from chemotherapy or radiotherapy alone than their combination. Additionally, patients with a high γδT cell abundance were more likely to benefit from immunotherapy. Finally, we established a radiomic model based on dynamic contrast-enhanced-MRI, which indicated the potential for estimating the γδT cell abundance for patients with TNBC. Our study provides novel insight and a theoretical basis for individualized therapy of patients with TNBC based on γδT cells.
- 7 April 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-16
Open AccessIntegrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer
Gamma-delta (γδ) T cells are a critical component of the tumor microenvironment and have been recognized as a promising biomarker and target for cancer therapy. Increasing evidence suggests that γδT cells play distinct roles in different cancers. However, the impact of γδT cells in breast cancer remains controversial. In this study, we investigated the role of γδT cells in breast cancer using a comprehensive approach, including bulk and single-cell sequencing, radiomics based on magnetic resonance imaging (MRI), genomic data, and immunohistochemistry. Single-cell RNA profiling was used to infer the potential lineage evolution of γδT cells and their interactions with other immune cells. Bulk RNA sequencing was included to uncover the heterogeneity in signaling pathways, as well as radiotherapy and immunotherapy responses, among patients with varying levels of γδT cell abundance. Genomic analysis was used to recognize the critical gene mutations with the infiltration of γδT cells. Immunohistochemistry was performed to validate the prognostic value of γδT cells in breast cancer patients. Lastly, radiomics was used to establish a correlation between the abundance of γδT cells and the features of MRI images. The γδT cell infiltration was closely associated with favorable prognosis in triple-negative breast cancer (TNBC) but not in other subtypes of breast cancer. γδT cells may exert antitumor effects through intrinsic lineage evolution or interact with antigen-presenting cells through ligand-receptor pairs. Patients with a high γδT cell abundance may benefit more from chemotherapy or radiotherapy alone than their combination. Additionally, patients with a high γδT cell abundance were more likely to benefit from immunotherapy. Finally, we established a radiomic model based on dynamic contrast-enhanced-MRI, which indicated the potential for estimating the γδT cell abundance for patients with TNBC. Our study provides novel insight and a theoretical basis for individualized therapy of patients with TNBC based on γδT cells.
- Open Access
- 21 January 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (4) , 1397-1412
Integration of Single-Cell and Bulk Transcriptomes to Identify a Poor Prognostic Tumor Subgroup to Predict the Prognosis of Patients with Early-stage Lung Adenocarcinoma
Background: Single-cell RNA sequencing (scRNA-seq) has emerged as a pivotal technology for investigating novel therapeutic targets in cancer. Despite its significance, there remains a scarcity of studies utilizing this technology to address treatment strategies specifically tailored for early-stage lung adenocarcinoma (LUAD). Consequently, this study aimed to investigate the tumor microenvironment (TME) characteristics and develop a prognostic model for early-stage LUAD.
- 21 January 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (4) , 1397-1412
Open AccessIntegration of Single-Cell and Bulk Transcriptomes to Identify a Poor Prognostic Tumor Subgroup to Predict the Prognosis of Patients with Early-stage Lung Adenocarcinoma
Background: Single-cell RNA sequencing (scRNA-seq) has emerged as a pivotal technology for investigating novel therapeutic targets in cancer. Despite its significance, there remains a scarcity of studies utilizing this technology to address treatment strategies specifically tailored for early-stage lung adenocarcinoma (LUAD). Consequently, this study aimed to investigate the tumor microenvironment (TME) characteristics and develop a prognostic model for early-stage LUAD.
- Open Access
- 18 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-15
Identification of the tumor metastasis-related tumor subgroups overexpressed NENF in triple-negative breast cancer by single-cell transcriptomics
Tumor metastasis is a continuous and dynamic process and is a major cause of tumor-related death in triple-negative breast cancer. However, this biological process remains largely unknown in triple-negative breast cancer. The emergence of single-cell sequencing enables a deeper understanding of the tumor microenvironment and provides a new strategy for discovering the potential mechanism of tumor metastasis. Herein, we integrated the single-cell expression profiling of primary and metastatic triple-negative breast cancer by Seurat package. Nine tumor cell subgroups were identified. Enrichment analysis suggested tumor subgroups (C0, C4) were associated with tumor metastasis with poor prognosis in TNBC. Weighted gene co-expression network was constructed and identified NENF was a metastasis-related gene. Subsequently, RT-qPCR, Immunohistochemistry, and western blot confirmed NENF is highly expressed in TNBC tissues. And cell function assays indicated NENF promote cell invasion and migration through regulating EMT in TNBC. Finally, TIDE and Connectivity Map database suggest the candidate drugs for targeting NENF. In conclusion, our findings provide a new insight into the progression and metastasis of TNBC and uncover NENF may be a prognostic biomarker and potential therapy targets.
- 18 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-15
Open AccessIdentification of the tumor metastasis-related tumor subgroups overexpressed NENF in triple-negative breast cancer by single-cell transcriptomics
Tumor metastasis is a continuous and dynamic process and is a major cause of tumor-related death in triple-negative breast cancer. However, this biological process remains largely unknown in triple-negative breast cancer. The emergence of single-cell sequencing enables a deeper understanding of the tumor microenvironment and provides a new strategy for discovering the potential mechanism of tumor metastasis. Herein, we integrated the single-cell expression profiling of primary and metastatic triple-negative breast cancer by Seurat package. Nine tumor cell subgroups were identified. Enrichment analysis suggested tumor subgroups (C0, C4) were associated with tumor metastasis with poor prognosis in TNBC. Weighted gene co-expression network was constructed and identified NENF was a metastasis-related gene. Subsequently, RT-qPCR, Immunohistochemistry, and western blot confirmed NENF is highly expressed in TNBC tissues. And cell function assays indicated NENF promote cell invasion and migration through regulating EMT in TNBC. Finally, TIDE and Connectivity Map database suggest the candidate drugs for targeting NENF. In conclusion, our findings provide a new insight into the progression and metastasis of TNBC and uncover NENF may be a prognostic biomarker and potential therapy targets.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (18) , 6002-6015
Integrating Bulk and Single-cell RNA-seq to Construct a Macrophage-related Prognostic Model for Prognostic Stratification in Triple-negative Breast Cancer
Background: Triple-negative breast cancer (TNBC) is a poor prognostic subtype of breast cancer due to limited treatment. Macrophage plays a critical role in tumor growth and survival. Our study intends to explore the heterogeneity of macrophage in TNBC and establish a macrophage-related prognostic model for TNBC prognostic stratification.
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (18) , 6002-6015
Open AccessIntegrating Bulk and Single-cell RNA-seq to Construct a Macrophage-related Prognostic Model for Prognostic Stratification in Triple-negative Breast Cancer
Background: Triple-negative breast cancer (TNBC) is a poor prognostic subtype of breast cancer due to limited treatment. Macrophage plays a critical role in tumor growth and survival. Our study intends to explore the heterogeneity of macrophage in TNBC and establish a macrophage-related prognostic model for TNBC prognostic stratification.
- Open Access
- 21 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (18) , 16837-16850
Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology
Background: Characterizing tumor microenvironment using single-cell RNA sequencing has been a promising strategy for cancer diagnosis and treatment. However, a few studies have focused on diagnosing papillary thyroid cancer (PTC) through this technology. Therefore, our study explored tumor microenvironment (TME) features and identified potential biomarkers to establish a diagnostic model for papillary thyroid cancer. Methods: The cell types were identified using the markers from the CellMarker database and published research. The CellChat package was conducted to analyze the cell–cell interaction. The SCEVAN package was used to identify malignant thyroid cells. The SCP package was used to perform multiple single-cell downstream analyses, such as GSEA analysis, enrichment analysis, pseudotime trajectory analysis, and differential expression analysis. The diagnostic model of PTC was estimated using the calibration curves, receiver operating characteristic curves, and decision curve analysis. RT-qPCR was performed to validate the expression of candidate genes in human papillary thyroid samples. Results: Eight cell types were identified in the scRNA-seq dataset by published cell markers. Extensive cell–cell interactions like FN1/ITGB1 existed in PTC tissues. We identified 26 critical genes related to PTC progression. Further, eight subgroups of PTC tumor cells were identified and exhibited high heterogeneity. The MDK/LRP1, MDK/ALK, GAS6/MERTK, and GAS6/AXL were identified as potential ligand-receptor pairs involved in the interactions between fibroblasts/endothelial cells and tumor cells. Eventually, the diagnostic model constructed by TRPC5, TENM1, NELL2, DMD, SLC35F3, and AUTS2 showed a good efficiency for distinguishing the PTC and normal tissues. Conclusions: Our study comprehensively characterized the tumor microenvironment in papillary thyroid cancer. Through combined analysis with bulk RNA-seq, six potential diagnostic biomarkers were identified and validated. The diagnostic model we constructed was a promising tool for PTC diagnosis. Our findings provide new insights into the heterogeneity of thyroid cancer and the theoretical basis for diagnosing thyroid cancer.
- 21 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (18) , 16837-16850
Open AccessIntegrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology
Background: Characterizing tumor microenvironment using single-cell RNA sequencing has been a promising strategy for cancer diagnosis and treatment. However, a few studies have focused on diagnosing papillary thyroid cancer (PTC) through this technology. Therefore, our study explored tumor microenvironment (TME) features and identified potential biomarkers to establish a diagnostic model for papillary thyroid cancer. Methods: The cell types were identified using the markers from the CellMarker database and published research. The CellChat package was conducted to analyze the cell–cell interaction. The SCEVAN package was used to identify malignant thyroid cells. The SCP package was used to perform multiple single-cell downstream analyses, such as GSEA analysis, enrichment analysis, pseudotime trajectory analysis, and differential expression analysis. The diagnostic model of PTC was estimated using the calibration curves, receiver operating characteristic curves, and decision curve analysis. RT-qPCR was performed to validate the expression of candidate genes in human papillary thyroid samples. Results: Eight cell types were identified in the scRNA-seq dataset by published cell markers. Extensive cell–cell interactions like FN1/ITGB1 existed in PTC tissues. We identified 26 critical genes related to PTC progression. Further, eight subgroups of PTC tumor cells were identified and exhibited high heterogeneity. The MDK/LRP1, MDK/ALK, GAS6/MERTK, and GAS6/AXL were identified as potential ligand-receptor pairs involved in the interactions between fibroblasts/endothelial cells and tumor cells. Eventually, the diagnostic model constructed by TRPC5, TENM1, NELL2, DMD, SLC35F3, and AUTS2 showed a good efficiency for distinguishing the PTC and normal tissues. Conclusions: Our study comprehensively characterized the tumor microenvironment in papillary thyroid cancer. Through combined analysis with bulk RNA-seq, six potential diagnostic biomarkers were identified and validated. The diagnostic model we constructed was a promising tool for PTC diagnosis. Our findings provide new insights into the heterogeneity of thyroid cancer and the theoretical basis for diagnosing thyroid cancer.